Developing new drugs to target a cancer protein called STAT5
Small-molecule degraders of STAT5
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10915589
This study is exploring a new way to help people with acute myeloid leukemia by developing small molecules that can target and break down a protein called STAT5, which is often too active in their cancer, with the hope of finding better treatment options.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10915589 on ClinicalTrials.gov |
What this research studies
This research focuses on creating small-molecule degraders that can effectively target and degrade the STAT5 protein, which is often overactive in certain types of leukemia. By using a novel approach called induced protein degradation, the researchers aim to inhibit the function of STAT5, which has been difficult to target with traditional therapies. The study involves designing and testing these degraders in human cancer cell lines and animal models to assess their effectiveness in reducing cancer cell growth and promoting tumor regression. If successful, this research could lead to new treatment options for patients with acute myeloid leukemia and other cancers associated with hyperactive STAT5.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or other cancers characterized by hyperactive STAT5.
Not a fit: Patients with cancers not associated with hyperactive STAT5 or those who do not have acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new, effective treatment options for patients suffering from acute myeloid leukemia and other cancers linked to STAT5.
How similar studies have performed: Other research has shown promise in targeting similar 'undruggable' proteins using induced protein degradation, suggesting potential for success in this approach.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, SHAOMENG — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: WANG, SHAOMENG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Treatment